Biohaven Ltd: Takeaways from R&D Day

Research evidence excerpt

Biohaven Ltd: Takeaways from R&D Day

Idea

May 28, 2026 04:01 AM GMT

Morgan Stanley & Co. LLCMBiohaven Ltd | North America Terence C Flynn, Ph.D.

Equity Analyst

Takeaways from R&D Day Terence.Flynn@morganstanley.comAlexander Yevdokimov, Ph.D. +1 212 761-2230

Research Associate

Alexander.Yevdokimov@morganstanley.com +1 212 761-2167

We offer our takeaways from BHVN’s 5/27 R&D Day, where Hailey Horowitz

mgmt reviewed two degrader programs advancing into Ph3 Research Associate

Hailey.Horowitz@morganstanley.com +1 212 761-5264

development (IgAN, Graves’ disease), updated incremental Chris Yu, J.D., Ph.D.

epilepsy and obesity datasets, and discussed ongoing early EquityChris.L.Yu@morganstanley.comAnalyst +1 212 761-2535

momentum across the company’s ADC platform. Connor M Massari

BHVN discussed ongoing advancement across the company’s late-stage pipeline Connor.Massari@morganstanley.com +1 212 761-2417

Damien H Kerner

portfolio, centered around extracellular degraders, epilepsy, obesity/body Research Associate

composition optimization and ADCs for cancer. Overall, the breadth of updates Damien.H.Kerner@morganstanley.com +1 212 761-3829

reinforced the company’s strategy of building a more concentrated portfolio of Morgan Stanley India Company Private Limited+

platform assets across a range of diseases. Saket Agarwal

Saket.Agarwal@morganstanley.com +91 22 6995-4012

BHVN disclosed that both MoDE/TRAP extracellular degraders (BHV-1300 /

BHV-1400) are expected to advance into pivotal development over the coming Biohaven Ltd (BHVN.N, BHVN UN)

weeks. Mgmt highlighted that the degrader platform remains a central strategic Biotechnology | United States of America

focus for the company, with the first extracellular degraders now progressing into Stock Rating Overweight